124 related articles for article (PubMed ID: 29257159)
21. The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure.
Ducreux M; Boige V; Goéré D; Deutsch E; Ezra P; Elias D; Malka D
Best Pract Res Clin Gastroenterol; 2007; 21(6):997-1014. PubMed ID: 18070700
[TBL] [Abstract][Full Text] [Related]
22. Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy.
Zagar TM; White RR; Willett CG; Tyler DS; Papavassiliou P; Papalezova KT; Guy CD; Broadwater G; Clough RW; Czito BG
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1126-31. PubMed ID: 22270161
[TBL] [Abstract][Full Text] [Related]
23. Localized Pancreatic Cancer: Multidisciplinary Management.
Coveler AL; Herman JM; Simeone DM; Chiorean EG
Am Soc Clin Oncol Educ Book; 2016; 35():e217-26. PubMed ID: 27249726
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.
Schwarz L; Katz MH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):727-40. PubMed ID: 26226907
[TBL] [Abstract][Full Text] [Related]
25. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.
White R; Lee C; Anscher M; Gottfried M; Wolff R; Keogan M; Pappas T; Hurwitz H; Tyler D
Ann Surg Oncol; 1999; 6(1):38-45. PubMed ID: 10030414
[TBL] [Abstract][Full Text] [Related]
26. Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma-A Critical Review of Randomised Trials.
Ejlsmark MW; Schytte T; Bernchou U; Bahij R; Weber B; Mortensen MB; Pfeiffer P
Curr Oncol; 2023 Jul; 30(7):6820-6837. PubMed ID: 37504359
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT.
Gkika E; Adebahr S; Kirste S; Schimek-Jasch T; Wiehle R; Claus R; Wittel U; Nestle U; Baltas D; Grosu AL; Brunner TB
Strahlenther Onkol; 2017 Jun; 193(6):433-443. PubMed ID: 28138949
[TBL] [Abstract][Full Text] [Related]
28. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
[TBL] [Abstract][Full Text] [Related]
29. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
[TBL] [Abstract][Full Text] [Related]
30. Ablative Radiotherapy Doses for Locally Advanced: Pancreatic Cancer (LAPC).
Crane CH; O'Reilly EM
Cancer J; 2017; 23(6):350-354. PubMed ID: 29189331
[TBL] [Abstract][Full Text] [Related]
31. Emerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer.
Berber B; Sanabria JR; Braun K; Yao M; Ellis RJ; Kunos CA; Sohn J; Machtay M; Teh BS; Huang Z; Mayr NA; Lo SS
Expert Rev Anticancer Ther; 2013 Apr; 13(4):481-7. PubMed ID: 23560842
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic body radiation therapy (SBRT) in pancreatic cancer: is it ready for prime time?
Chang BW; Saif MW
JOP; 2008 Nov; 9(6):676-82. PubMed ID: 18981547
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant therapy for pancreatic cancer: an evolving paradigm.
Zhu AX; Clark JW; Willett CG
Surg Oncol Clin N Am; 2004 Oct; 13(4):605-20, viii. PubMed ID: 15350937
[TBL] [Abstract][Full Text] [Related]
34. [Extreme hypofractionated radiation therapy for pancreatic cancer].
Rouffiac M; Ghirardi S; Chevalier C; Bessières I; Peignaux-Casasnovas K; Truc G; Créhange G
Cancer Radiother; 2021 Oct; 25(6-7):692-698. PubMed ID: 34284971
[TBL] [Abstract][Full Text] [Related]
35. Sequential and/or concurrent hypofractionated radiotherapy and concurrent chemotherapy in neoadjuvant treatment of advanced adenocarcinoma of the pancreas. Outcome and patterns of failure.
Zimmermann FB; Schuhmacher C; Lersch C; Bernhardt B; Pickel P; Siewert JR; Molls M; Jeremic B
Hepatogastroenterology; 2004; 51(60):1842-6. PubMed ID: 15532839
[TBL] [Abstract][Full Text] [Related]
36. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
[TBL] [Abstract][Full Text] [Related]
37. Current standards and new innovative approaches for treatment of pancreatic cancer.
Conroy T; Bachet JB; Ayav A; Huguet F; Lambert A; Caramella C; Maréchal R; Van Laethem JL; Ducreux M
Eur J Cancer; 2016 Apr; 57():10-22. PubMed ID: 26851397
[TBL] [Abstract][Full Text] [Related]
38. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery.
Mazzola R; Fersino S; Aiello D; Gregucci F; Tebano U; Corradini S; Di Paola G; Cirillo M; Tondulli L; Ruffo G; Ruggieri R; Alongi F
Strahlenther Onkol; 2018 Sep; 194(9):835-842. PubMed ID: 29696321
[TBL] [Abstract][Full Text] [Related]
39. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
40. Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma.
Pollom EL; Koong AC; Ko AH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):741-59. PubMed ID: 26226908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
